Company Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-12 pm EDT 5-day change 1st Jan Change
26.88 USD +3.86% Intraday chart for Beam Therapeutics Inc. +16.46% -1.25%

Business Summary

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Number of employees: 346

Sales per Business

USD in Million2022Weight2023Weight Delta
Genetic Medicines
100.0 %
61 100.0 % 378 100.0 % +520.01%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
61 100.0 % 378 100.0 % +520.01%

Managers

Managers TitleAgeSince
Chief Executive Officer 46 16-12-31
President 55 18-01-31
Director of Finance/CFO 47 19-07-31
Chief Tech/Sci/R&D Officer - 23-03-20
Chief Tech/Sci/R&D Officer 60 21-03-14
Chief Tech/Sci/R&D Officer 59 18-06-30
Corporate Officer/Principal 47 19-08-31
Human Resources Officer 61 17-07-31
General Counsel 59 19-03-31
Comptroller/Controller/Auditor 63 19-01-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 54 19-10-09
Director/Board Member 60 21-11-04
Director/Board Member 73 18-04-30
Director/Board Member 68 21-01-09
Chief Executive Officer 46 16-12-31
Director/Board Member 57 Dec. 13
Director/Board Member 51 18-11-14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 82,311,067 81,121,692 ( 98.56 %) 0 98.56 %

Shareholders

NameEquities%Valuation
ARK Investment Management LLC
9.941 %
8,182,174 9.941 % 192 M $
Vanguard Fiduciary Trust Co.
9.207 %
7,578,768 9.207 % 178 M $
BlackRock Advisors LLC
7.548 %
6,212,853 7.548 % 146 M $
Farallon Capital Management LLC
5.481 %
4,511,753 5.481 % 106 M $
Morgan Stanley Investment Management, Inc.
5.010 %
4,123,575 5.010 % 97 M $
Fidelity Management & Research Co. LLC
4.562 %
3,755,010 4.562 % 88 M $
3,731,192 4.533 % 87 M $
Nikko Asset Management Americas, Inc.
2.869 %
2,361,817 2.869 % 55 M $
Milky Way Investments Group Ltd.
2.851 %
2,346,934 2.851 % 55 M $
Darwin Global Management Ltd.
2.575 %
2,119,598 2.575 % 50 M $

Company contact information

Beam Therapeutics, Inc.

238 Main Street 9th floor

02142-1016, Cambridge

+

http://www.beamtx.com
address Beam Therapeutics Inc.(BEAM)
  1. Stock Market
  2. Equities
  3. BEAM Stock
  4. Company Beam Therapeutics Inc.